RxDoctor Payments Data

Arvind Jariwala, MD

Internal Medicine · Raleigh, NCNPI 1457346439

Payments from drug & device makers

$2,888in general payments, 2019–2025

Across 195 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$635
  • Amgen$273
  • Lilly USA, LLC$253
  • Abbott$225
  • Johnson & Johnson$197
  • Pfizer$196
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$2,888100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,888 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$137,195
Medicare patients
230
Services billed
5,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin65$90,679
OzempicSemaglutide40$52,803
TrulicityDulaglutide37$50,619
MounjaroTirzepatide33$40,174
EliquisApixaban40$33,503
JanuviaSitagliptin Phosphate11$17,609
TradjentaLinagliptin12$16,190
XareltoRivaroxaban18$15,407
GlyxambiEmpagliflozin/Linagliptin16$14,575
Xigduo XrDapaglifloz Propaned/Metformin16$13,643
Breo ElliptaFluticasone/Vilanterol23$12,805
RybelsusSemaglutide12$9,065
Tresiba Flextouch U-100Insulin Degludec20$8,852
InvokanaCanagliflozin12$6,901
Repatha SureclickEvolocumab12$6,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$163$121,44493 claims
Lilly USA, LLCTrulicity, Mounjaro$253$90,79370 claims
Novo NordiskOzempic, Rybelsus$635$61,86852 claims
PfizerEliquis, Paxlovid$196$34,93277 claims
Johnson & JohnsonXarelto, Invokana$197$22,30930 claims
MerckJanuvia$31$17,60911 claims
GSKBreo Ellipta$58$12,80523 claims
AbbVieSynthroid$89$2,19719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →